Spesolimab Phase II data
New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
Search
The Unwearable Collection - The GPP patient experience
The Unwearable Collection™ is a fashion line based on the experiences of patients living with generalized pustular psoriasis, designed by Bart Hess.
Generalized pustular psoriasis is not ‘sensitive’ content
Learn about the impact that a lack of online visibility can have on people living with this chronic, inflammatory skin disease.
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
U.S. FDA grants priority review for spesolimab in GPP
U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA
Frida Dunger Johnsson, Executive Director of IFPA and panelist at the generalized pustular psoriasis (GPP) Forum, reflects on a momentous day
Living with GPP
Video content showing a patient’s perspective of living with generalized pustular psoriasis (GPP), a rare skin condition
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
Live well with Generalized Pustular Psoriasis (GPP)
Unmet needs in Generalized Pustular Psoriasis (GPP)
Generalised-Pustular-Psoriasis-Infographic
What is GPP? GPP is a rare and chronic autoinflammatory skin disease with recurrent episodes of exacerbations or flares
The GPP Forum Report
The generalized pustular psoriasis (GPP) Forum Report summarizes and highlights the important moments form the multistakeholder GPP Forum
The GPP Charter
The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
SPEVIGO®
SPEVIGO® (spesolimab) is a novel, humanized, selective antibody for the treatment of generalized pustular psoriasis (GPP) flares.
GPP: there is more than you see
Generalized Pustular Psoriasis is a rare neutrophilic skin condition. Watch an animation to learn about its recurrent nature and how it affects people
The Unwearable Collection™
The Unwearable Collection™ was created to bring the physical and emotional burden of living with GPP to life.
SPEVIGO CHMP positive opinion new indications
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody Netherton Syndrome
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
The Unwearable Collection™: Fashion Inspired by GPP
An introduction to The Unwearable Collection™: fashion inspired by the experiences of living with GPP, designed by Bart Hess
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
GPP
GPP
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award